2350533
Project Grant
Overview
Grant Description
Sttr phase I: commercializing architect-directed DNA synthesis -the broader impact of this small business technology transfer (STTR) phase I project is to expand innovation in the biotechnology sector through the development of a new DNA synthesis technology. DNA synthesis is a key enabling technology for synthetic biology and biotechnology.
Traditional DNA synthesis methods build DNA one nucleotide at a time and can only synthesize short strands of DNA due to fidelity limitations. These short strands of DNA can be assembled into larger DNA fragments but this process is sequence dependent and often fails. This results in high costs, delayed timelines, and even an inability to complete certain research goals.
This project seeks to overcome these challenges by developing an entirely novel DNA synthesis technology that will significantly reduce costs and lead times, while also enabling the synthesis of long and complex DNA. These advances will significantly accelerate and enable innovation and development of new therapeutics, biomanufacturing, agriculture, and more.
The proposed project is focused on the commercial development of novel DNA synthesis technology. This technology is a hierarchical approach to DNA synthesis that relies on small 2-5 BP DNA precursors that can be enzymatically assembled into larger DNA sequences in an exponential fashion (eg, 2 BP to 4 BP to 8 BP to 16 BP, etc).
Funding in this program will be used to i) develop new methods for ensuring higher fidelity DNA precursors, ii) reduce synthesis costs by streamlining synthesis reactions, as well as iii) characterize quality control approaches. If successful, this project will pave the way for high fidelity DNA synthesis at low costs and rapid turnaround times.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria. - Subawards are planned for this award.
Traditional DNA synthesis methods build DNA one nucleotide at a time and can only synthesize short strands of DNA due to fidelity limitations. These short strands of DNA can be assembled into larger DNA fragments but this process is sequence dependent and often fails. This results in high costs, delayed timelines, and even an inability to complete certain research goals.
This project seeks to overcome these challenges by developing an entirely novel DNA synthesis technology that will significantly reduce costs and lead times, while also enabling the synthesis of long and complex DNA. These advances will significantly accelerate and enable innovation and development of new therapeutics, biomanufacturing, agriculture, and more.
The proposed project is focused on the commercial development of novel DNA synthesis technology. This technology is a hierarchical approach to DNA synthesis that relies on small 2-5 BP DNA precursors that can be enzymatically assembled into larger DNA sequences in an exponential fashion (eg, 2 BP to 4 BP to 8 BP to 16 BP, etc).
Funding in this program will be used to i) develop new methods for ensuring higher fidelity DNA precursors, ii) reduce synthesis costs by streamlining synthesis reactions, as well as iii) characterize quality control approaches. If successful, this project will pave the way for high fidelity DNA synthesis at low costs and rapid turnaround times.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria. - Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Durham,
North Carolina
27705-3888
United States
Geographic Scope
Single Zip Code
Dinya Dna was awarded
Project Grant 2350533
worth $275,000
from National Science Foundation in July 2024 with work to be completed primarily in Durham North Carolina United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
STTR Phase I
Title
STTR Phase I: Commercializing Architect-directed DNA Synthesis
Abstract
The broader impact of this Small Business Technology Transfer (STTR) Phase I project is to expand innovation in the biotechnology sector through the development of a new DNA synthesis technology. DNA synthesis is a key enabling technology for synthetic biology and biotechnology.
Traditional DNA synthesis methods build DNA one nucleotide at a time and can only synthesize short strands of DNA due to fidelity limitations. These short strands of DNA can be assembled into larger DNA fragments but this process is sequence dependent and often fails. This results in high costs, delayed timelines, and even an inability to complete certain research goals. This project seeks to overcome these challenges by developing an entirely novel DNA synthesis technology that will significantly reduce costs and lead times, while also enabling the synthesis of long and complex DNA. These advances will significantly accelerate and enable innovation and development of new therapeutics, biomanufacturing, agriculture, and more.
The proposed project is focused on the commercial development of novel DNA synthesis technology. This technology is a hierarchical approach to DNA synthesis that relies on small 2-5 bp DNA precursors that can be enzymatically assembled into larger DNA sequences in an exponential fashion (eg, 2 bp to 4 bp to 8 bp to 16 bp, etc). Funding in this program will be used to i) develop new methods for ensuring higher fidelity DNA precursors, ii) reduce synthesis costs by streamlining synthesis reactions, as well as iii) characterize quality control approaches. If successful, this project will pave the way for high fidelity DNA synthesis at low costs and rapid turnaround times.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BT
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 7/8/24
Period of Performance
7/1/24
Start Date
6/30/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2350533
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
DW82ZYPMUHQ5
Awardee CAGE
None
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Modified: 7/8/24